Browsing by Author "Yazici O."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Predictive factors for the development of brain metastases in patients with malignant melanoma: A study by the Anatolian society of medical oncology
    (2014) Gumusay O.; Coskun U.; Akman T.; Ekinci A.S.; Kocar M.; Erceleb O.B.; Yazici O.; Kaplan M.A.; Berk V.; Cetin B.; Taskoylu B.Y.; Yildiz A.; Goksel G.; Alacacioglu A.; Demirci U.; Algin E.; Uysal M.; Oztop I.; Oksuzoglu B.; Dane F.; Gumus M.; Buyukberber S.
    Background: The development of brain metastases (BMs) was associated with poor prognosis in melanoma patients. Patients with BMs have a median survival of <6 months. Melanoma is the third most common tumor to metastasize to the brain with a reported incidence of 10-40 %. Our aim was to identify factors predicting development of BMs and survival. Patients and methods: We performed a retrospective analysis of 470 melanoma patients between 2000 and 2012. The logistic regression analyses were used to identify the clinicopathological features of primary melanoma that are predictive of BMs development and survival after a diagnosis of brain metastases. Results: There were 52 patients (11.1 %) who developed melanoma BMs during the study period. The analysis of post-BMs with Kaplan-Meier curves has resulted in a median survival rate of 4.1 months (range 2.9-5.1 months). On logistic regression analysis site of the primary tumor on the head and neck (p = 0.002), primary tumor thickness (Breslow >4 mm) (p = 0.008), ulceration (p = 0.007), and pathologically N2 and N3 diseases (p = 0.001) were found to be significantly associated with the development of BMs. In univariate analysis, tumor thickness and performance status had a significant influence on post-BMs survival. In multivariate analysis, these clinicopathologic factors were not remained as significant predictive factors. Conclusions: Our results revealed the importance of primary tumor characteristics associated with the development of BMs. Ulceration, primary tumor thickness, anatomic site, and pathologic ≥N2 disease were found to be significant predictors of BMs development. © 2013 Springer-Verlag Berlin Heidelberg.
  • No Thumbnail Available
    Item
    The effect of the gastrectomy on survival in patients with metastatic gastric cancer: A study of ASMO
    (Future Medicine Ltd., 2016) Yazici O.; Özdemir N.; Duran A.O.; Menekşe S.; Nahit Şendur M.A.; Karaca H.; Göksel G.; Arpaci E.; Hacibekiroʇlu I.; Bilgetekin I.; Kaçan T.; Özkan M.; Aksoy S.; Aksoy A.; Çokmert S.; Uysal M.; Elkiran E.T.; Çiçin I.; Büyükberber S.; Zengin N.
    Aim: To investigate the role of surgical resection of primary tumor on overall survival (OS) in advanced gastric cancer patients at the time of diagnosis. Patients & methods: The survival rates of metastatic gastric cancer patients whose gastric primary tumor was resected at time of diagnosis were compared with metastatic gastric cancer patients whose primary tumor was nonresected. Results: The median progression-free survival and OS in operated and nonoperated group were 10 versus 6, 14 versus 9 months, respectively (p < 0.001). In multivariate analysis, gastric resection of primary tumor, Eastern Cooperative Oncology Group performance status, second-line chemotherapy had a significant effect on OS (hazard ratio [HR]: 0.52 [95% CI: 0.38-0.71], HR: 0.57 [95% CI: 0.42-0.78], HR: 1.48 [1.09-2.01]; p ≤ 0.001, p = 0.001 and p = 0.012, respectively). Conclusion: Subpopulations of patients with metastatic gastric cancer might benefit from surgical removal of primary tumor. © 2016 Future Medicine Ltd.